Thermo Fisher Scientific Inc. will acquire Olink Holding AB in a deal that values the pharmaceutical products and services company at about $3.1 billion.
Both boards approved Thermo Fisher’s proposal for $26 per share in cash, representing a premium of about 74% of the closing price for Olink’s American Depository Shares on Monday. The deal is expected to be complete by mid-2024.
Thermo Fisher’s purchase of the Uppsala, Sweden-based company enhances its capabilities in protein analysis.
Read the full story on Bloomberg here.